Clinical Trial: The efficacy and safety of high-dose dual therapy versus bismuth quadruple therapy in eradicating Helicobacter pylori in patients with type 2 diabetes: A randomized controlled non-inferiority study (China)

Posted On: 2026-09-18

China, Sept. 18 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'The efficacy and safety of high-dose dual therapy versus bismuth quadruple therapy in eradicating Helicobacter pylori in patients with type 2 diabetes: A randomized controlled non-inferiority study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132758

Registration Time: 2026/09/18

Type: Interventional study

Primary Sponsor: The First Hospital of Lanzhou University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=311803

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: The efficacy and safety of high-dose dual therapy versus bismuth quadruple therapy in eradicating Helicobacter pylori in patients with type 2 diabetes: A randomized controlled non-inferiority study (China)